FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available. The following may be used to respond to questions. It is estimated that about 130,000 people in the United States will be diagnosed with colorectal cancer this year.
Primary treatment consists of surgery with or without adjuvant chemotherapy or radiation.
In 1996, Camptosar was granted accelerated approval for treatment of patients with metastatic carcinoma of the colon or rectum whose disease had recurred or progressed following 5-FU based therapy.